title: Caffeine eye drops protect against UV-B cataract.
abstract: The purpose of this study was to investigate if topically applied caffeine protects against in vivo ultraviolet radiation cataract and if so, to estimate the protection factor. Three experiments were carried out. First, two groups of Sprague-Dawley rats were pre-treated with a single application of either placebo or caffeine eye drops in both eyes. All animals were then unilaterally exposed in vivo to 8 kJ/m(2) UV-B radiation for 15 min. One week later, the lens GSH levels were measured and the degree of cataract was quantified by measurement of in vitro lens light scattering. In the second experiment, placebo and caffeine pre-treated rats were divided in five UV-B radiation dose groups, receiving 0.0, 2.6, 3.7, 4.5 or 5.2 kJ/m(2) UV-B radiation in one eye. Lens light scattering was determined after one week. In the third experiment, placebo and caffeine pre-treated rats were UV-B-exposed and the presence of activated caspase-3 was visualized by immunohistochemistry. There was significantly less UV-B radiation cataract in the caffeine group than in the placebo group (95% confidence interval for mean difference in lens light scattering between the groups = 0.10 ± 0.05 tEDC), and the protection factor for caffeine was 1.23. There was no difference in GSH levels between the placebo- and the caffeine group. There was more caspase-3 staining in UV-B-exposed lenses from the placebo group than in UV-B-exposed lenses from the caffeine group. Topically applied caffeine protects against ultraviolet radiation cataract, reducing lens sensitivity 1.23 times.
authors: Gullstrand Lab., Ophthalmology, Dept. of Neuroscience, Uppsala University, Sweden. martin.kronschlager@neuro.uu.se
authors: Martin
authors: M
authors: Kronschläger
authors: Stefan
authors: S
authors: Löfgren
authors: Zhaohua
authors: Z
authors: Yu
authors: Nooshin
authors: N
authors: Talebizadeh
authors: Shambhu D
authors: SD
authors: Varma
authors: Per
authors: P
authors: Söderberg
mesh_terms: D000287:Administration, Topical; D000818:Animals; D002110:Caffeine / Q000008:administration & dosage*; D053148:Caspase 3 / Q000378:metabolism; D002386:Cataract / Q000175:diagnosis / Q000378:metabolism / Q000517:prevention & control*; D000697:Central Nervous System Stimulants / Q000008:administration & dosage*; D019084:Fluorescent Antibody Technique, Indirect; D005978:Glutathione / Q000378:metabolism; D007908:Lens, Crystalline / Q000378:metabolism / Q000473:pathology / Q000528:radiation effects*; D008297:Male; D009883:Ophthalmic Solutions; D011829:Radiation Dosage; D011833:Radiation Injuries, Experimental / Q000175:diagnosis / Q000378:metabolism / Q000517:prevention & control*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012542:Scattering, Radiation; D014466:Ultraviolet Rays / Q000009:adverse effects*
chemical_list: D000697:Central Nervous System Stimulants; D009883:Ophthalmic Solutions; D002110:Caffeine; D053148:Caspase 3; D005978:Glutathione
keywords: caffeine; cataract; protection factor; ultraviolet radiation
references: Trans Ophthalmol Soc U K. 1985;104 ( Pt 1):1-10
references: 3855332
references: Arch Ophthalmol. 1964 Aug;72:178-88
references: 14162940
references: Exp Eye Res. 2010 Sep;91(3):369-77
references: 20599969
references: Ann Intern Med. 1983 May;98(5 Pt 1):641-53
references: 6342491
references: Curr Eye Res. 1985 Dec;4(12):1289-95
references: 4085257
references: Acta Ophthalmol. 2010 Nov;88(7):779-85
references: 20102349
references: Free Radic Res. 1996 Mar;24(3):225-10
references: 8728124
references: Invest Ophthalmol Vis Sci. 1998 Dec;39(13):2681-7
references: 9856778
references: Br Med J (Clin Res Ed). 1987 Nov 21;295(6609):1293-4
references: 3120982
references: Am J Ophthalmol. 2003 Sep;136(3):506-12
references: 12967805
references: Anal Biochem. 1968 Oct 24;25(1):192-205
references: 4973948
references: Mol Vis. 2010 Dec 08;16:2626-33
references: 21179241
references: Acta Ophthalmol. 2008 Mar;86(2):188-95
references: 17944982
references: N Engl J Med. 1988 Dec 1;319(22):1429-33
references: 3185661
references: Food Chem Toxicol. 1991 Jan;29(1):1-6
references: 1847890
references: J Ocul Pharmacol Ther. 2000 Apr;16(2):121-35
references: 10803423
references: Acta Ophthalmol (Copenh). 1990 Feb;68(1):44-52
references: 2336933
references: Ophthalmic Res. 1990;22(5):271-9
references: 2090981
references: Invest Ophthalmol Vis Sci. 2012 Jan 25;53(1):248-52
references: 22167097
references: J Ocul Pharmacol Ther. 2008 Oct;24(5):439-44
references: 18788993
references: Invest Ophthalmol Vis Sci. 2000 Oct;41(11):3539-43
references: 11006249
references: Dev Ophthalmol. 2002;35:70-5
references: 12061280
references: J Ocul Pharmacol Ther. 2010 Feb;26(1):73-7
references: 20148663
references: Biochim Biophys Acta. 1996 Jun 13;1282(1):63-70
references: 8679661
references: Clin Chim Acta. 2000 May;295(1-2):141-54
references: 10767400
references: Dev Ophthalmol. 2002;35:21-31
references: 12061276
references: Prog Retin Eye Res. 2003 Sep;22(5):657-82
references: 12892645
references: Clin Ophthalmol. 2011;5:1623-9
references: 22140308